By 2016, the start-up was valued at $1 billion, with the MindMaze VR technology making its way into hospitals across Europe and Asia. In-patient devices like MindMotion Pro, and portable devices like MindMotion Go, have already helped more than 1,300 patients. Receiving FDA approval in 2017, Tadi is preparing to launch MindMaze in the US, where strokes are the fifth leading cause of death. Recently, MindMaze also acquired Neuro Motor Innovations, a company that also utilizes game therapy as a complementary treatment for stroke patients. Tadi sees MindMaze as more of a passion project, one he hopes will revolutionize the way patients relearn to move and think, while motivating them to take recovery into their own hands.